Silibinin reverses drug resistance in human small-cell lung carcinoma cells

Cancer Letters

Volumn 339, Issue 1, 2013, Pages 102-106

  Sadava, David ^a   Kane, Susan E ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Chemotherapy; Lung carcinoma; Multidrug resistance; Sensitization; Silibinin

Indexed keywords

CALCEIN ACETOXYMETHYL ESTER; CASPASE 3; CISPLATIN; DNA FRAGMENT; DOXORUBICIN; ESTER DERIVATIVE; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN; SILIBININ; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL STRAIN SCLC; CELL STRAIN VPA17; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; EFFUSION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

APOPTOSIS; CHEMOTHERAPY; LUNG CARCINOMA; MULTIDRUG RESISTANCE; SENSITIZATION; SILIBININ;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; SILYMARIN; SMALL CELL LUNG CARCINOMA;

SILYBUM MARIANUM;

EID: 84883465250     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.017     Document Type: Article

References (22)

1. Govindan R., Page N., Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006, 24:4539-4544.
2. Principles and Practice of Lung Cancer 2010, Lippincott Williams Wilkins, Philadelphia, pp. 847-865. fourth ed. H.I. Pass, D.P. Carbone, D.H. Johnson, J.D. Minna, G. Scagliotti, A.T. Turrisi (Eds.).
3. Nishio W., Nakamura T., Koh Y., Suzuki T., Fukumoto H., Saijo N. Drug resistance in lung cancer. Curr. Opin. Oncol. 1999, 11:109-115.
4. Ladas E., Kroll D.J., Kelly K.A. Milk Thistle. Encyclopedia of Dietary Supplements 2005, Marcel Dekker, New York. P.M. Coates, M.R. Blackman, G.M. Cragg, M. Levine, J.D. White (Eds.).
5. Wagner H., Diesel P., Seitz M. Arzneimittelforschung 1974, 24:466-471.
6. Kim N.C., Graf T.N., Sparacino C.M., Wani M.C., Wall M.E. Complete isolation and characterization of silibins and isosilybins from milk thistle. Org. Biomol. Chem. 2003, 1:1684-1689.
7. Lahari-Chaterjee M., Katijar S.K., Mohan R.R., Agarwal R.A. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999, 59:622-632.
8. Singh R., Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol. Carcinogenesis 2006, 45:436-442.
9. Singh R., Raina K., Sharma G., Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse. Clin. Cancer Res. 2008, 14:3380-7773.
10. Flaig T.W., Gustafson D.L., Su L.-J., Zirolli J., Curghton F., Harrison G., Pierson A., Agarwal R., Glode L.M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs 2007, 25:139-146.
11. Singh R., Deep G., Chittezehath M., Kaur M., Dwyer-Nield L., Malkinson A., Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J. Natl. Cancer Inst. 2006, 98:846-855.
12. Singh R., Mallikarjuna G., Sharma G., Tyagi A., Chan D., Agarwal C., Agarwal R. Oral silibinin inhibits lung tumor growth in athymic nude mice. Clin. Cancer Res. 2004, 10:8641-8647.
13. Yan Y., Wang Y., Tan Q., Lubet R., You M. Efficacy of deguelin and silibinin on benzo(a)pyrene induced lung tumorigenesis in A/J mice. Neoplasia 2005, 7:1-53-1057.
14. Chittezhath M., Deep G., Singh R., Agarwal C., Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down regulates iNOS in human lung carcinoma A549 cells. Mol. Cancer Ther. 2008, 7:1817-1826.
15. Ramasamy K., Agarwal R. Multi-targeted therapy of cancer by silymarin. Cancer Lett. 2008, 269:352-362.
16. Minato K., Kanzawa F., Nishio K., Nakagawa K., Fujiwara Y., Saijo N. Characterization of an etoposide-resistant human small-cell lung carcinoma line. Cancer Chemother. Pharmacol. 1990, 26:313-327.
17. Sadava D., Ahn J., Zhan M., Pang M.-L., Ding J., Kane S.E. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother. Pharmacol. 2002, 49:261-266.
18. Sadava D., Hamman W. RNA interference against MDR1 but not MRP1 reverses drug resistance in small-cell lung carncer cells. J. Cancer Mol. 2007, 3:91-94.
19. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi H. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 1993, 268:21493-21496.
20. Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
21. Earnshaw W., Martins S., Kaufmann S. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Ann. Rev. Biochem. 1999, 69:383-424.
22. Zaffaroni N., Daidone M. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Update 2002, 5:65-72.